3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
137
Breast Neoplasms
10
Neoplasm Metastasis
8
Neoplasms
5
Bulbo-Spinal Atrophy, X-Linked
5
Triple Negative Breast Neoplasms
4
Salivary Gland Neoplasms
2
Prostate Adenocarcinoma
2
Osteoporosis
2
Lower Urinary Tract Symptoms
2
Hirsutism
2
Thrombocytosis
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Stage I Prostate Adenocarcinoma
1
Sexual Dysfunction, Physiological
1
Recurrence
1
Primary Myelofibrosis
1
Primary Dysautonomias
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Paget Disease, Extramammary
1
PSA Level Greater Than Two
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Castrate Metastatic Prostate Cancer
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
Sunitinib
3
avelumab
2
Nutrition Assessment
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
etelcalcetide hydrochloride
1
enzalutamide
1
cabozantinib
1
bicalutamide
1
atezolizumab
1
aldesleukin
1
Valsartan
1
VMBP protocol
1
Stents
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Lysine Acetyltransferase 5
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Kidney Diseases
×
bicalutamide
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled